Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.-Reference-Cited by-同舟云学术

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Published:2022-06 Issue:6 Volume:84 Page:795-813
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Liu Xinxue,Munro Alasdair P S,Feng Shuo,Janani Leila,Aley Parvinder K,Babbage Gavin,Baxter David,Bula Marcin,Cathie Katrina^ORCID,Chatterjee Krishna,Dejnirattisai Wanwisa,Dodd Kate,Enever Yvanne,Qureshi Ehsaan,Goodman Anna L.,Green Christopher A,Harndahl Linda^ORCID,Haughney John^ORCID,Hicks Alexander,van der Klaauw Agatha A.,Kwok Jonathan,Libri Vincenzo^ORCID,Llewelyn Martin J^ORCID,McGregor Alastair C,Minassian Angela M.^ORCID,Moore Patrick,Mughal Mehmood,Mujadidi Yama F,Holliday Kyra^ORCID,Osanlou Orod^ORCID,Osanlou Rostam,Owens Daniel R,Pacurar Mihaela,Palfreeman Adrian,Pan Daniel^ORCID,Rampling Tommy^ORCID,Regan Karen,Saich Stephen,Serafimova Teona^ORCID,Saralaya Dinesh,Screaton Gavin R,Sharma Sunil,Sheridan Ray,Sturdy Ann,Supasa Piyada,Thomson Emma C,Todd Shirley,Twelves Chris,Read Robert C.,Charlton Sue,Hallis Bassam,Ramsay Mary,Andrews Nick,Lambe Teresa,Nguyen-Van-Tam Jonathan S,Cornelius Victoria^ORCID,Snape Matthew D,Faust Saul N^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference25 articles.

1. OurWorldinData. COVID-19 vaccine booster doses administered per 100 people. 2021. Available from: https://ourworldindata.org/grapher/covid-vaccine-booster-doses-per-capita.

2. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial;Munro;Lancet,2021

3. Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England;Andrews;Nat Med,2022

4. Lyngse F.P., Kirkeby C.T., Denwood M., Christiansen L.E., Mølbak K., Møller C.H., et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish Households. medRxiv. 2022: 2022.01.28. 22270044.

5. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift;Cameroni;Nature,2021

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination;Heliyon;2024-01

2. Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination;Human Vaccines & Immunotherapeutics;2023-11-28

3. Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study;Cureus;2023-09-19

4. Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru;Vaccine: X;2023-08

5. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses;BMJ;2023-07-24